Dachman v. Shalala

46 F. Supp. 2d 419, 1999 U.S. Dist. LEXIS 5192, 1999 WL 222672
CourtDistrict Court, D. Maryland
DecidedApril 13, 1999
DocketCivil AMD 96-873
StatusPublished
Cited by6 cases

This text of 46 F. Supp. 2d 419 (Dachman v. Shalala) is published on Counsel Stack Legal Research, covering District Court, D. Maryland primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dachman v. Shalala, 46 F. Supp. 2d 419, 1999 U.S. Dist. LEXIS 5192, 1999 WL 222672 (D. Md. 1999).

Opinion

MEMORANDUM

DAVIS, District Judge.

Plaintiff, Sarah Rebecca Dachman, M.D., an Orthodox Jew and a former employee of the Food and Drug Administration (“FDA”), an agency of the Department of Health & Human Services, instituted this action under Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. § 2000e (“Title VII”). Her claims include one or more of the following theories: sex discrimination, race discrimination, religious discrimination, retaliation and hostile environment. 1 As redress, Dr. Dachman seeks declaratory, injunctive and various forms of corrective relief and damages.

In this memorandum, I shall address all claims except plaintiffs termination claims. Plaintiff essentially alleges that her supervisors at the FDA discriminated against her on the basis of sex, race and religion, took retaliatory actions against her, and intentionally created an abusive and hostile work environment in violation of Title VII over the four year period culminating in her termination in early 1998. I have carefully considered the parties’ submissions and conclude that no hearing is necessary. Local Rule 105.6 (1997). For the reasons stated below, I shall grant defen *422 dant’s motion for summary judgment. 2

1. UNDISPUTED FACTS OR FACTS IN LIGHT MOST FAVORABLE TO PLAINTIFF

A. Introduction

I present here a full factual account of the evidence and information contained in the record. For purposes of ruling on the motions, plaintiff is entitled to have “her version of matters in dispute accepted, and the benefit of all favorable inferences,” Fisher v. Maryland Dept. of Housing Community Dev., 32 F.Supp.2d 257, 262 (D.Md.1998), at least so long as there is proper support in the record under Fed. R.Civ.P. 56 for her version of events.

Dr. Dachman graduated with honors from the George Washington University School of Medicine in 1983. She became employed by the FDA in 1988. Initially, she worked part-time and later she became a full-time employee.

Dr. Dachman worked as a medical officer at the Center for Biologies Evaluation and Research (“CBER”), where she was responsible for reviewing drug licensing applications, investigational new drug applications and responding to inquiries regarding such applications. Up until at least 1995, Dr. Dachman’s job performance evaluations reflected that her performance was “fully successful” to “excellent.”

Dr. Dachman began her career at the FDA with a core group of other medical officers. This core group included, but was not limited to, Dr. William Schwieter-man, Dr. Margaret Mitrane, Dr. Patricia Keegan and Dr. Karen Weiss. From time to time during the events at issue in this case, Drs. Weiss, Schwieterman and Kee-gan, respectively, were Dr. Dachman’s first level supervisors. Dr. Jay Siegel was her second level supervisor. Dr. Weiss and Dr. Siegel adhere to the teachings of Reform Judaism and Conservative Judaism, respectively.

*423 Dr. Dachman had a collegial relationship with her colleagues when she first began working at the FDA. However, the nature of her relationship with her colleagues eventually deteriorated into rancor and strife. Dr. Dachman eventually filed innumerable charges of discrimination against her, supervisors with the Equal Employment Opportunity (“EEO”) office. Dr. Dachman blames her supervisors and co-workers for the failure, of the collegial relationship she had with them. Defendant Shalala contends, however, that Dr. Dachman’s unprofessional and inappropriate workplace behavior and poor job performance were the major factors that contributed to the disintegration of the relationship and ultimately led to her termination from employment at the FDA. In any event, the record reflects that the relationship began to sour in 1993 and, on February 6, 1998, Dr. Dachman was discharged from her position at the FDA

Through Dr. Dachman’s eyes, there were two major events that culminated in her discharge from employment with the FDA. First, she believes that her protests to Dr. Siegel that his sexual advances towards her were unwelcomed caused him to turn against her. Second, she believes that Dr. Schwieterman acted deliberately to have her arrested for allegedly leaving a threatening message on his office voice mail. (Dr. Dachman also contends, alternatively, that the threatening voice mail message was actually left by one of her coworkers who mimicked Dr. Dachman’s distinct accent.). As for Dr. Schwieterman, Dr. Dachman has come to believe that his motives were based on an aversion to her religious beliefs. Dr. Dachman further believes that her supervisors and coworkers, with discriminatory animus, conspired to discredit her professionally and to have her removed from her job.

B. Evidence of Unwelcomed Sexual Conduct by Dr. Siegel

In 1990, Dr. Dachman became the key medical reviewer of a clinical trial application to study a drug that dissolves cardiac blood clots. The project was dubbed “GUSTO.”, It was the largest such project that had been submitted to CBER. In October 1993, an amendment to the license application was submitted, and Dr. Dach-man was appointed chair of the “GUSTO” Product License Application (“PLA”) advisory committee. In addition, she became the lead reviewer of the trial data.

On occasion, Drs. Dachman and Siegel worked together closely. Dr. Dachman asserts that beginning in early 1993, Dr. Siegel began touching her on the forearm, always on or near the same spot. Dr. Dachman estimates that between early 1993 and April 1994, Dr. Siegel touched her forearm approximately ten times. A-though Dr. Dachman felt uncomfortable with this contact, she did not voice any objection to the touching because she did not know Dr. Siegel’s motivation. In May 1994, however, Dr. Dachman began to suspect that Dr. Siegel’s motives were sexual in nature and she asked him to stop touching her. Her suspicions about his motives derived from her observation that he never touched her when he was angry with her. Dr. Dachman told him that it bothered her when he touched her because, as an Orthodox Jew, she is.not accustomed to casual contact with men. Dr. Dachman testified that Dr. Siegel touched her only three times after she confronted him about his behavior.

Dr. Siegel does not deny that he touched Dr. Dachman on the forearm on numerous occasions. He 'testified, however, that he was only trying get her attention and to point out something that they were reviewing. He testified that despite his efforts to respect Dr. Dachman’s wishes, she had to remind him on occasion.

One stormy evening in May 1994, Drs. Siegel and Dachman were working in his office on the GUSTO project. Dr. Dach-man testified that without warning, Dr. Siegel turned off the lights.' Dr. Dachman feared that Dr. Siegél was going to sexually attack her. Immediately, she shouted *424 “Jay, what the hell are-you doing? I’m a married woman!” Dr. Siegel responded immediately and turned the lights back on.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hagans v. Raimondo
D. Maryland, 2024
Dachman v. United States
73 Fed. Cl. 508 (Federal Claims, 2006)
Blount v. Thompson
400 F. Supp. 2d 838 (D. Maryland, 2004)
Pueschel v. Veneman
185 F. Supp. 2d 566 (D. Maryland, 2002)
Kilpatrick v. Riley
98 F. Supp. 2d 9 (District of Columbia, 2000)
Miller v. Runyon
88 F. Supp. 2d 461 (M.D. North Carolina, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
46 F. Supp. 2d 419, 1999 U.S. Dist. LEXIS 5192, 1999 WL 222672, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dachman-v-shalala-mdd-1999.